Fosamprenavir Calcium Salt, Inhibitor

Fosamprenavir Calcium Salt

Cat. Num. AAA5759048

• Purity: 98.00%
• Synonyms: Fosamprenavir Calcium Salt; GW433908G; inhibitor

• Purity/Purification: 98.00%
• Form/Format: Solid. Powder

• Solubility: DMSO: 1.8mg/mL (2.89mM) Need ultrasonic and warming; H2O: 0.25mg/mL (0.40mM) Need ultrasonic and warming; DMSO: 5mg/mL (28.04mM); (<1mg/ml refers to the product slightly soluble or insoluble)
• Formula: C25H34CaN3O9PS
• SMILES: [Ca++].CC(C)CN(C[C@@H](OP([O-])([O-])=O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)c1ccc(N)cc1
• CAS Number: 226700-81-8
• Target & IC50: HIV
• In Vitro: Oral gavage of DATS significantly retarded growth of PC-3 xenografts in athymic mice without causing weight loss. For instance, 20 days after starting therapy, the average tumor volume in control mice was approximately 3-fold higher compared with DATS-treated mice. Tumors from DATS-treated mice exhibited a markedly higher count of apoptotic bodies compared with control tumors. Consistent with the results in cultured PC-3 cells, the DATS-mediated suppression of PC-3 xenograft growth correlated with induction of proapoptotic proteins Bax and Bak. Although DATS treatment,inhibited migration of cultured PC-3 cells in association with down-regulation of vascular endothelial growth factor receptor-2 protein, formation of new blood vessels was comparable in tumors of control and DATS-treated mice as judged by CD31 immunostaining[1].
• Preparation and Storage: Store at -20 degree C for 3 years powder; -80 degree C for 2 years in solvent

Structure

Related Product Information for Fosamprenavir Calcium Salt, inhibitor

Fosamprenavir Calcium Salt (GW433908G) is a phosphate ester prodrug of the antiretroviral protease inhibitor Amprenavir, with improved solubility[1]. Anti-HIV infection[1].

Product Categories/Family for Fosamprenavir Calcium Salt, inhibitor

Microbiology/Virology; HIV Protease; Proteases/Proteasome

References

Falcoz C, et al. Pharmacokinetics of GW433908, a prodrug of amprenavir, in healthy male volunteers. J Clin Pharmacol. 2002 Aug;42(8):887-98.
Xiao D, Lew K L, Kim Y A, et al. Diallyl Trisulfide Suppresses Growth of PC-3 Human Prostate Cancer Xenograft In vivo in Association with Bax and Bak Induction[J]. Clinical Cancer Research, 2006, 12(22):6836-6843.
Michael P, Silvia S. Dietary Bioactive Diallyl Trisulfide in Cancer Prevention and treatment,J]. International Journal of Molecular Sciences, 2017, 18(8):1645-.